



# aviso importante

## GOVERNMENT OF PUERTO RICO DEPARTMENT OF HEALTH NOTICE OF REGULATION AMMENDMENT

### TO AMEND SECRETARY OF HEALTH'S REGULATION FOR THE CONTROL OF FABRICATION, DISTRIBUTION, DISPENSATION AND DISPOSITION OF CONTROLLED SUBSTANCES TO ADD DECLARATORY ORDER NO. 37 OF THE SECRETARY OF HEALTH, INCLUDING XILAZINE UNDER CLASSIFICATION II

By virtue of the powers and authority conferred by Act No. 81 of March 14, 1912, as amended, and Act No. 38 of June 30, 2017, the Secretary of Health proposes to amend the Secretary of Health's Regulation for the Control of Fabrication, Distribution, Dispensation and Disposition of Controlled Substances (Reglamento Núm. 153 del Departamento de Salud, Reglamento Núm. 8598 de 29 de mayo de 2015), for the purpose of incorporating Declaratory Order Number 37 of the Secretary of Health to said regulation.

Declaratory Order No. 37 classifies and includes Xylazine in Classification II of controlled substances, including in said classification all types of drugs within the specific chemical designation of this substance. This Order No. 37 was adopted pursuant to official alerts issued by the Drug Enforcement Administration (DEA), the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA).

A. Other names or terms by which this drug is known are:

1. Xilacina (Xilazine o Xilazyne)
2. Anestesia de caballo (Horse anesthetic)
3. Trank / Tranq
4. Tranq dope
5. Sleep-cut
6. Philly dope
7. Zombie drug

B. Brand names for Xylazine are:


1. Anesvet
2. Butomidor
3. Dexdomitor
4. Rompun
5. Sedivet (Nombre de marca d)
6. Xylazil
7. RomPon

C. Name used in the Dominican Republic for Xilaxin: Diamino/Diamine.

The proposed amendment is available on the Health Department's website: [www.salud.gov.pr](http://www.salud.gov.pr).

A virtual public hearing will be held on June 16, 2023, beginning at 10:00 a.m. Anyone interested in participating in the public hearing should send their email address to: [wsostre@salud.pr.gov](mailto:wsostre@salud.pr.gov) and will receive an invitation with the instructions to connect to the Virtual Public Hearing. People are encouraged to submit their comments in writing within thirty (30) days following the date of publication of this notice to the following email address: [wsostre@salud.pr.gov](mailto:wsostre@salud.pr.gov).

In San Juan, Puerto Rico, May 25, 2023.

  
CARLOS MELLADO LÓPEZ, MD  
Secretary of Health

